The PRWIRE Press Releases https:// 2019-12-03T01:27:16Z InterSystems Named a Leader in 2019 Gartner Magic Quadrant for Operational Database Management Systems 2019-12-03T01:27:16Z intersystems-named-a-leader-in-2019-gartner-magic-quadrant-for-operational-database-management-systems SYDNEY, Australia, December 3, 2019 – InterSystems, a global leader in high-performance information technology platforms that drive mission critical applications across healthcare, business, and government, today announced that Gartner, Inc. has recognised the company as a Leader in its 2019 Gartner Magic Quadrant for Operational Database Management Systems. InterSystems has been included in the annual report since 2013. Last year, InterSystems introduced the InterSystems IRIS™ Data Platform, a complete, unified data platform that enables organisations to simplify and accelerate the development, deployment and maintenance of mission-critical and highly reliable applications. Its first specialised edition, InterSystems IRIS for Health, empowers healthcare organisations to rapidly develop the healthcare applications that manage the world’s most critical data, combining analytical and transaction processing with native interoperability for all data types. “The InterSystems IRIS Data Platform powers some of the most high-volume, mission-critical and innovative applications across multiple industries — all of which require not only great technology, but also superior support and stability. As problem solvers, we continue to partner closely with our customers and application partners to expand these capabilities,” said Scott Gnau, vice president of data platforms at InterSystems. “We will continue to accelerate our investments in innovation, partnering and support. Our entire team appreciates the recognition by Gartner and our customers.” A complimentary copy of the 2019 Magic Quadrant for Operational Database Management Systems can be viewed here. InterSystems is also recognised as a Jan. 2019 Gartner Peer Insights Customers’ Choice for Operational Database Management Systems. Gartner Disclaimers Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organisation and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates. About InterSystems InterSystems is the information engine that powers some of the world’s most important applications. In healthcare, business, government, and other sectors where lives and livelihoods are at stake, InterSystems has been a strategic technology provider since 1978. InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries. For more information, please visit Pheburane Listed on the Pharmaceutical Benefits Scheme 2019-11-28T09:13:34Z pheburane-listed-on-the-pharmaceutical-benefits-scheme Pheburane Listed on the Pharmaceutical Benefits Scheme MELBOURNE, Australia, December 1st, 2019 – Orpharma Pty Ltd. and Lucane Pharma SA. are pleased to announce the listing of Pheburane on the Pharmaceutical Benefits Scheme (PBS). Pheburane will be funded from the 1st December 2019 for the treatment of Urea Cycle Disorders (UCDs).   Pheburane was approved by Australia’s TGA in May 2017 for the treatment of UCDs. Listing on the PBS will make the product readily available to all patients diagnosed with the condition. The Product Information can be accessed here. The Consumer Medicine Information can be accessed here.   Pheburane is an improved formulation of Sodium Phenylbutyrate, a standard treatment for UCD patients to remove ammonia. Sodium phenylbutyrate has a very strong bitter and salty taste which may compromise compliance to treatment, especially in children. Pheburane offers a formulation where the taste is completely masked.   PBS Prescribing Information   Max.Qty Packs No. of Repeats Prescribing code Prescribers 3 5 11865L Medical Practitioner Nurse Practitioner    About Orpharma Orpharma is an Australian pharmaceutical company focused on the supply of orphan, paediatric and emerging therapeutics. Orpharma is Australia’s first and only one stop shop for metabolic products supplying a range of low protein food, medical nutrition and medicines. Orpharma is collaborating with global leaders in biotechnology and pharmaceuticals to deliver therapies to patients in need. The company’s current product portfolio includes innovative medicines targeting rare metabolic diseases, cancer and anti-infectives. For more information about Orpharma visit   About Lucane Pharma French Lucane Pharma S/A, Paris, incorporated in 2009 is part of Dutch based privately owned company Eurocept Pharmaceuticals Holding. The company specializes in the development and commercialization of medicinal products targeting rare disorders.   Its’ products will provide patients with a real improvement in the management of their disease: new products for diseases currently lacking effective treatment, improved formulations of existing products, new presentations fulfilling a specific need, existing products not available in most countries. Perkins researcher develops tool to target the right vein, the first time 2019-11-25T23:47:03Z perkins-researcher-develops-tool-to-target-the-right-vein-the-first-time A medical device start-up established at the Harry Perkins Institute of Medical Research, is aiming to help patients undergoing one of the most common medical procedures.   Along with Emergency Consultant Dr Katherine Arenson and Telethon Kids Researcher Nick Buckley, Perkins Vascular Engineer Nik Bappoo designed a technology to help doctors more successfully cannulate patients with difficult vascular access.   For most patients admitted into hospital, having a cannula or needle placed into their arm is a necessary procedure to enable doctors to either take blood for tests or provide fluids or medication.   These cannulas can be difficult to place successfully in certain patient groups, in particular obese patients, with some patients requiring up to 5 or more attempts.   Other tools such as the ultrasound can be used to assist cannulation, however other applications such as pregnancy scans and cardiac imaging have higher priority. Ultrasound imaging also requires extensive experience.   Perkins Vascular Engineering Researcher Nik Bappoo, said that the start-up, called VeinTech, was founded from the development of a simple imaging technology to assist clinicians with this issue.    “The overall cost to the healthcare system is much greater than the wasted hardware and includes clinician time and increased complications,” Nik said.    “Lifesaving tests and treatment can be drastically delayed and infection rates increase with each cannula attempt. Multiple attempts also cause significant pain and anxiety to the patient.”   “We set out to create a solution that would be simple to use while reducing cannulation attempts in difficult access patients.”   Bappoo who led the development of the technology known as the VeinWave, said in just six months the team had identified a largely unmet clinical need and developed a solution to address the need through the Perth Biodesign program, derived from Stanford University   "We are proud of our progress in the course and I hope to encourage entrepreneurial research and showcase the translation happening at the Perkins,” Nik said.    The technology has this week been awarded the first prize at the 2019 Perth Biodesign Final Presentations.  New drug that breaks down the ‘barbed wire’ around some cancers 2019-11-13T05:40:34Z new-drug-that-breaks-down-the-barbed-wire-around-some-cancers Some solid tumours are so stiff they make a cracking noise when they are cut by researchers on the laboratory bench.   The fibrous nature of liver, pancreatic and some breast cancers make them difficult to treat. However, five years of research by a team of Perth scientists has resulted in the development of a novel, non-toxic agent that can deliver drugs to the cancer cells embedded in the fibrous matrix.   Research published in EMBO Molecular Medicine showed a non-toxic therapeutic agent boosted immune cells to selectively remove the fibrous scar tissue allowing cancer treatments to reach their target.    Dr Juliana Hamzah, head of the Targeted Drug Delivery, Imaging and Therapy Laboratory at the Harry Perkins Institute of Medical Research said by breaking down the fibrous matrix of stiff tumours the patient’s own immune system paved the way for drug treatments to take effect.   “The cancer is like a wound, and a way that our body tries to repair the wound is to grow a scar tissue around it, but that scar tissue makes it very difficult to get to the cancer cells to destroy them.    “It is stiff, non-cellular, has very few blood vessels and impenetrable. The scar tissue is not only a physical barrier but it constricts blood vessels which are key pathways for delivering cancer treatment.    “The barrier around some cancers, such as liver cancer, pancreatic cancer and some breast cancers is like barbed wire.    “We have developed a non-toxic agent that does not affect surrounding healthy tissue.    “The agent activates immune cells to release enzymes that digest the scar tissue. This allows more cancer killing immune cells to enter the tumour. Our results show that removal of the fibrous tissue dramatically eliminates the drug delivery barrier.     “Tumours treated with the drug we’ve developed are more permeable to anti-tumour immune cells and cancer treatments”, Dr Hamzah said.   The research data have been validated in four laboratories including the Harry Perkins Institute of Medical Research in Perth, the School of Engineering at The University of Western Australia, Sanford Burnham Prebys Medical Discovery Institute, California, USA, and the University California Davis, California, USA. Dr Hamzah says that now the drug has been proven to have a positive impact on fibrosis, or scar tissue, she is investigating whether it can be used to prevent malignant cancer by treating the early stages of fibrosis in liver cancer.  “If you take liver cancer, it doesn’t start immediately as cancer, it starts as fibrosis, cirrhosis, which then develops into liver cancer.    “Because chronic tissue fibrosis can lead to cancer we aim to investigate whether early treatment with our drug of the pre-cancerous stage, such as liver fibrosis, could prevent development of malignant cancer.   Testing of the drug is due to commence using human tissue biopsies. Australian women turning to cannabis to treat endometriosis symptoms 2019-11-12T00:30:34Z australian-women-turning-to-cannabis-to-treat-endometriosis-symptoms AUSTRALIA, Sydney – November 12, 2019 – A new study published today in Journal of Obstetrics Gynaecology Canada has found one in eight Australian women with endometriosis use cannabis to alleviate pain and other symptoms, rating the plant based medicine as the most effective way to self-manage the disorder. Researchers from NICM Health Research Institute, Western Sydney University and UNSW Sydney surveyed 484 Australian women with endometriosis between the ages of 18 and 45 to determine the types of strategies they used to self-manage symptoms.  They found more than three quarters of Australian women with endometriosis are turning to self-management strategies including breathing techniques, yoga, dietary changes, heat and cannabis. Cannabis was ranked as the most effective treatment by women.  The women said that along with reducing pain, they felt that cannabis significantly reduced symptoms of nausea and vomiting, gastrointestinal symptoms, problems with their sleep, feelings of depression and anxiety.  Women using cannabis also reported a decrease in the medication that they normally took for their endometriosis symptoms, with just over half saying they decreased their medication by 50 per cent or more. Reported side effects were mild and relatively rare.  Endometriosis is a chronic condition where tissue similar to the lining of the uterus is found outside the uterus, and commonly causes pelvic pain and fatigue, with many women reporting significant negative impact on many aspects of their life including education and work, friendships, and sexual relationships.  In Australia, around one in nine women born between 1973–78 were diagnosed with endometriosis by age 40–44. The condition may cost up to $9.7 billion in Australia per year, mostly through productivity losses. Aside from surgery, current treatments for endometriosis include use of oral contraceptive or progestogens, and non-steroidal anti-inflammatory drugs, which do not always provide adequate pain control, or have side effects that are hard to tolerate for some women. Opioid analgesics are often prescribed for pain, however there is a risk of dependency and overdose.  Lead author on the study, NICM Health Research Institute Research Fellow and Coordinator of the Australian Medicinal Cannabis Research and Education Collaboration, Justin Sinclair said that due to the limitations of existing medical treatments for endometriosis, women are turning to self-care or lifestyle interventions for symptom relief and research is needed into the effectiveness of these self-management strategies. 
 “Cannabis has a long history of use in the ancient and scientific literature for various conditions such as period pain, however until now nothing has been investigated for cannabis being used for endometriosis,” Mr Sinclair said. “Past research has demonstrated that certain compounds within cannabis known as cannabinoids exert analgesic and anti-inflammatory activity. Our research sought to determine the prevalence, tolerability, and self-reported effectiveness of cannabis in women with endometriosis.” Although the study showed promising results for the use of cannabis for endometriosis symptoms, Mr Sinclair cautioned that cannabis use was not without risk, however the reported rates of adverse effects were low in their study. “One in ten women in the study who used cannabis reported an undesirable effect such as drowsiness, rapid heartbeat, or increased anxiety,” he said. According to Chief Investigator on the study NICM Health Research Institute’s Dr Mike Amour, Australian law currently requires legal medicinal cannabis use to follow specific, regulated pathways that limit prescription by this method; however, self-reported illicit use of cannabis remains relatively common in Australian women with endometriosis. “Due to the timing of when the survey was administered, most if not all of the women in the survey would have been using illicit cannabis as access to medicinal cannabis was still in its infancy,” Dr Armour said. “This means we don’t have any information about the different varieties of cannabis that women were using, or what might have been in the cannabis that was being used as it was derived from illicit sources which are not quality assured. Also, this was a self-reported survey, which can lead to over or under estimation of the positive or the negative effects. “Further research is needed to assess the effectiveness of quality controlled medicinal cannabis and women with endometriosis.” The paper, Cannabis use, a self-management strategy among Australian women with endometriosis: results from a national online survey, is available online at Journal of Obstetrics Gynaecology Canada. Hospitals Share Digital Transformation Experiences at InterSystems Asia Pacific Healthcare Customer Meeting 2019-11-04T00:28:13Z hospitals-share-digital-transformation-experiences-at-intersystems-asia-pacific-healthcare-customer-meeting-1 BANGKOK, November 4, 2019 – Hospitals across the region have come together to share their digital transformation experiences at the first annual Healthcare Asia Pacific Customer Meeting held by InterSystems, a global leader in information technology platforms for health, business and government.   Over 100 delegates from more than 30 hospitals in China, Indonesia, Thailand, Malaysia, Australia, and New Zealand heard from some of the most technologically advanced healthcare providers in the region about their use of new digital capabilities including big data analysis, predictive analytics, artificial intelligence (AI), and machine learning.   Leading hospitals revealed how they were using advanced technologies to support transformational changes such as population health and value-based care initiatives. The Bangkok event – with a theme of “creating the future of care” – also outlined strategies to mitigate clinical safety and cyber security risks.   At the same event, attendees learned about the latest interoperability, mobility and advanced clinical technologies from InterSystems, as well as strategies to improve clinician electronic medical record (EMR) system satisfaction and adoption from healthcare IT data and insights analyst firm KLAS Research.   Healthcare Unbounded In his opening remarks, Luciano Brustia, Regional Managing Director – Asia Pacific for InterSystems, said that despite all the innovations, breakthroughs, and increases in life expectancy, healthcare systems are still full of information silos and barriers between different people, processes, and organizations. In fact a new survey by InterSystems showed that 55% of private hospitals in South East Asia see system interoperability challenges as a barrier to digital transformation.   “Along with our customers and partners, InterSystems is creating the future of care, something we call Healthcare Unbounded, where all the different care givers are empowered with a complete and easy-to-use picture of each patient and are coordinated with each other,” said Brustia. “Advanced interoperability using standards like FHIR will extend the EMR to collect information that wasn’t available to caregivers in the past. And healthcare providers will understand their populations better, using data analytics and AI to predict healthcare risks and develop new treatments based on what works and what doesn’t work in the real world.”   Using AI to make clinical predictions Kenny Lim, CIO of Bumrungrad International Hospital in Bangkok and Eric Widen, Co-founder & CEO of HBI Solutions, revealed how Bumrungrad had used HBI’s Spotlight solution to analyze data in its InterSystems TrakCare® EMR and employ machine learning and AI technology. This enabled the hospital to make predictions about the onset of sepsis, the risk of mortality, length of hospital stay, and likelihood of patients developing chronic diseases.   Bumrungrad’s vision is to provide “world-class holistic healthcare by 2022”, said Lim, providing patients with care and treatments for both immediate health problems and overall wellbeing. According to the InterSystems survey, Bumrungrad is one of only 5% of private hospitals in South East Asia that have deployed AI, a figure expected to rise to 56% over the next five years.   Focusing on patient-centered, smart healthcare Dr. Jenny Shao, Health Information Systems Director for United Family Healthcare in China, shared key learnings from UFH’s 11-year journey with TrakCare. UFH has already transformed from a clinician-centered to a patient-centered approach to care, and is currently transforming from a focus on the patient to a focus on the whole person.   Dr. Shao also previewed UFH’s next transformation to smart healthcare, smart hospital and community, applying technology to support “P4 healthcare” which was predictive, preventative, personalized, and participatory.   Mitigating safety and cyber security risks While minimizing clinical risks is a key driver of digitization, delegates heard about strategies to mitigate the clinical safety and cyber security risks that also come with digital healthcare.   InterSystems Clinical Safety Managers from China, Thailand, and Australia/New Zealand spoke about the company’s clinical safety framework, which identifies and assesses risks and proactively takes action to mitigate them. Attendees learned about how they could become personally involved in patient safety initiatives at their own hospitals and partner with InterSystems to further improve patient safety for all TrakCare EMR users.   According to Ken Mortensen, Data Protection Officer for InterSystems, systems interoperability and the cloud have created a bigger attack surface for hackers. However, the cloud now also enables healthcare providers to centralize security controls to increase systems security. Mortensen recommended a readiness assessment to better understand the cyber threats healthcare providers face and to assess whether hospitals have the right security measures in place to deal with them and whether staff are properly trained about privacy and security.   Mobility and TrakCare Open Access Delegates learned about the expanded capabilities of the latest version of TrakCare, built on the InterSystems IRIS for Health™ data platform, and how IRIS has boosted systems interoperability, cloud scalability and healthcare big data capabilities. They also heard how mobility is improving the user experience wherever care is delivered.   Dimitri Fane, Director of Product Management for TrakCare, demonstrated how the product’s mobile-enabled user interface supports all clinical workflows, including operating theatre bookings and administration, maternity and nursing care plans, dynamic patient lists, and a patient journey tracker.   InterSystems also introduced Asia Pacific customers to TrakCare Open Access, enabling them to develop or deploy solutions based on the SMART on FHIR standard. “We are actively seeking Asia Pacific customers to partner with us around SMART on FHIR to innovate and enhance the TrakCare experience to take full advantage of their EMR data,” said Fane.                        About InterSystems InterSystems is the information engine that powers some of the world’s most important applications. In healthcare, business, government, and other sectors where lives and livelihoods are at stake, InterSystems has been a strategic technology provider since 1978. InterSystems is a privately held company headquartered in Cambridge, Massachusetts (USA), with offices worldwide, and its software products are used daily by millions of people in more than 80 countries. For more information, please visit MedAdvisor to Offer the Convenience of Medication Delivery to its Pharmacy and Patient Network 2019-11-01T02:24:53Z medadvisor-to-offer-the-convenience-of-medication-delivery-to-its-pharmacy-and-patient-network-1 Melbourne, 1 November 2019 --- MedAdvisor Limited, Australia’s leading digital medication management company, is pleased to announce it has signed an agreement with Kings Transport, one of Australasia’s premier Metropolitan transport and logistics providers, that will enable MedAdvisor’s 3,300 network pharmacies to offer the convenience of medication delivery to their patients. Kings was chosen by MedAdvisor due to their national footprint, extensive experience in the safe and appropriate delivery of medication and endorsement by the Pharmacy Guild of Australia. MedAdvisor and Kings will partner to drive volume of orders in app and through pharmacy. The agreement will allow MedAdvisor to enable a same day medication delivery fulfilment service to its 3,300 network pharmacies for use with their ~12 million Australian customers, including (but not limited to) those who order directly via the MedAdvisor app and SMS.   Of the ~12m Australian customers serviced by its pharmacy network, MedAdvisor has over 1.2m who are digitally connected either through its highly rated consumer app or SMS reminder service.  Over $300m worth of medication orders pass through the integrated MedAdvisor platform each year, and its digitally connected patients are well placed to take advantage of the convenience of integrated medication pre-payment and delivery from their preferred pharmacy. Access to Kings delivery fulfilment service will be provided seamlessly as part of each network pharmacy’s PlusOne subscription and MedAdvisor will receive a share of the delivery fee. Following technical integration, the initial rollout will commence in H2 FY20, focussing on major metropolitan centres. Following the recent activation of Pay in Advance functionality, MedAdvisor will now provide seamless integration and workflow for pharmacies to coordinate deliveries that includes dynamic pricing, payment facilities and now home delivery with driver tracking. Robert Read, CEO of MedAdvisor commented: “Patients are demanding greater convenience in their healthcare experience. MedAdvisor already partners with over 55% of Australian pharmacies to help them deliver unparalleled convenience to their customers. By adding enhanced convenience services like delivery to their customer proposition, community pharmacies can deepen the vital relationship between patients and their regular pharmacist. Having these services activated in readiness for ePrescribing is a huge opportunity and risk mitigation for community pharmacy.” Barry Thompson, CEO of Kings Transport commented: “Kings is proud to partner with MedAdvisor to provide distribution solutions with a commitment to emerging market services and technologies. We have had a long-standing presence within the wellness industry, so we clearly understand the strict guidelines of transporting and delivering medications. Our customer service and driver excellence form a crucial component to our value offering, with technology that provides additional security and inventory management benefits.” ---ENDS--- About MedAdvisor    MedAdvisor is a world class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor’s highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over one million users through ~55% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with Adheris in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018, was recognised in the AFR Fast 100.   About Kings Kings is an Australian owned and operated company established in 1991 offering client customised and on-demand transport and logistics services within the Australasian region. Their strengths lie in the Health, Industrial and Consumer Home Delivery segments; partnering with blue chip clients to develop industry specific knowledge and expertise.  Kings mission is to deliver excellence in logistics with a commitment to People First, Strong Capabilities, Safety Always and Sustainability. Kings launched Australia's first 100% Electric Trucks (OEM) in 2017 and partner with Greenfleet to offset emissions.  MedAdvisor announces its September 2019 Quarterly Report and 4C 2019-10-31T00:56:19Z september-2019-quarterly-report-and-4c MedAdvisor Limited, Australia’s leading digital medication management company, has today released its Appendix 4C Report for the three-month period to 30 September 2019 and is pleased to provide an update of the progress during the period. Financial Update The Company reported $2.1m (unaudited) in quarterly revenue, an uplift of 18.8% from Q1 FY19 ($1.8m). Annualised Recurring Revenue (ARR)[1] derived as at September from pharmacy SaaS sales increased ~4.7% compared to June 2019, despite total revenue being 7.7% lower than Q4  primarily due to the timing of health program delivery. Operating Cash Flow Breakdown of the June 2019 Quarter $’000 AUSTRALIA INTERNATIONAL TOTAL Total Operating Cash flow 2,211   2,211 BAU Cash outflows (1,746)   (1,746) Net BAU Cash Flows       Growth Cash Inflows - 73 73 Growth Cash Outflows (2,092) (1,177) (3,269) Net Growth Cash Flows (2,092) (1,104) (3,196) Net Cash Flow (1,627) (1,104) (2,731)   The company reported total cash receipts of $2.8m in Q1 FY20, with operating cash receipts of $2.3m (versus $1.9m (+23.1%) in Q1 FY19). Net cash used in operating activities was in line with expectations at ($2.7m) vs ($1.9m) in Q1 FY19. After allowing for one-off adjustments[2], underlying net cash used in operating activities was $2.2m. MedAdvisor closed the quarter with $2.3m in cash, prior to raising $17m in October.   Capital Raising In early October 2019, MedAdvisor raised $17m at $0.05 per share, an 11% premium to the share price at that time. Following its investment of $11m, HMS (NASDAQ:HMSY), a leading US healthcare analytics and technology business, became the largest shareholder with a 13% holding, joining existing strategic investors EBOS Group (ASX:EBO) and Sigma (ASX:SIG) on MedAdvisor’s share register. The funding provides MDR with the capital required to execute opportunities identified to date in each market. These funds will be used for continued investment in MedAdvisor’s technology, sales and support, to drive success in the US and UK as well as support the MedAdvisor Zuellig Pharma joint venture in South East Asia. Business Updates Australia MedAdvisor has over 3,300 pharmacy customers who subscribe to PlusOne, the Software-as-a-Service (“SaaS”) offering. These pharmacies collectively serve ~12m Australian customers, and of those, MedAdvisor digitally connects its pharmacy customers to over 1.2 million patients. In early October, MedAdvisor signed a new 3-year agreement with pharmacy retail giant Chemist Warehouse. The Chemist Warehouse agreement is expected to generate $5m revenue over its 3-year term. The figure includes recurring SaaS licence fees, patient messaging fees and new revenue streams from Health Programs facilitated and distributed by MedAdvisor. The audience of patients eligible for both digital and in store Health Programs is expected to significantly increase. US In the US, MedAdvisor has signed its first top 10 global pharmaceutical company as a Health Programs customer through its partnership with Adheris. The initial revenue from this Health Program is not material, however it does represent an important milestone and proof point for the company’s US market entry strategy. MedAdvisor remains focused and on track to generate revenue from this, and potential additional Health Programs in the US in Q2/Q3 FY20 in collaboration with its US partner, Adheris. Off the back of the recent investment by HMS; an expert in supporting health funders including health insurers and government to improve patient health outcomes and reduce costs, HMS will work with MedAdvisor to leverage our capabilities for customers in the US and Australia. Asia The Singapore-based joint venture, ZP MedAdvisor Pte. Ltd. (“ZPM”) is on track for its rollout plans in the Philippines and Malaysia. In the Philippines, ZPM expects revenue to begin in Q2 FY20 as previously advised. To that end ZPM will begin rollout of the MedAdvisor app for MedExpress’ 1.5m regular customers before the end of H1 FY20. In Malaysia, ZPM recently signed agreements with Klinify to distribute Health Programs to a pool of over 2 million patients. Under the Klinify agreement, ZPM will support more than 900 Malaysian doctors to offer digital Health Programs to their patients. Revenue from Malaysia is expected to commence in H2 FY20. UK In the UK, MedAdvisor secured its first customer and recognised its first revenue following the agreement executed with Day Lewis Pharmacy Group in August. The Day Lewis Pharmacy Group is one of the largest independent pharmacy chains in the UK owning over 270 pharmacies and servicing over 1 million customers. A Day Lewis branded version of the MedAdvisor consumer app is being customised for their patients to order and manage their medications and is expected to begin roll out as planned in Q3 FY20.   Robert Read, CEO of MedAdvisor commented: “The business is continuing to pursue its growth objectives and our strategy to achieve these objectives is well funded. We have achieved key milestones in all our operating markets. Generating first revenues in the US, UK and Asia is our major focus, to that end, we have now received our first cash inflow from the UK, signed our first revenue generating deal in the US and our joint venture is progressing well. Validation of our offering is demonstrated by our customer wins across both pharmacy and pharmaceutical companies in all markets. MedAdvisor’s proposition to help address the global problem of medication non-adherence is being recognised by major players in the world’s largest markets. We have significantly increased the audience of patients that can receive our programs that improve health literacy and help people take their medication safely, effectively and on time in Australia and around the world.” ---ENDS--- [1] Calculated as the final month of the Quarter SaaS revenue plus new sales within that month that will generate revenue in future periods [2] Includes a one-off adjustment to the companies timing of tax related payments and implementation fees of the new finance system. Australian Neuroscientist Awarded the 2019 Advance Global Award 2019-10-17T22:56:59Z australian-neuroscientist-awarded-the-2019-advance-global-award The Overall Winner of the 2019 Advance Awards has been announced as US-based Australian neuroscientist and physical therapist Dr David Putrino. The award makes Dr Putrino Advance's Global Australian of the Year. Dr Putrino has been recognised worldwide for his game-changing work at the Abilities Research Center, a laboratory devising innovative ways to use virtual reality and video games to improve patient health and rehabilitation, based in New York.   Dr Putrino was awarded this great honour at the Advance Awards Ceremony and Gala Dinner in Sydney last night, which recognises and celebrates the outstanding achievements of Australians living and working offshore. He was also awarded the Healthcare category award for his exceptional commitment to research and development of innovative technology solutions for individuals in need of accessing better healthcare. Dr Putrino’s work explores the use of virtual reality as a low-cost and scalable treatment for chronic neuropathic pain: a condition affecting millions of people worldwide with few effective treatments. His game-based interventions have been shown to accelerate the process of neuroplasticity and lead to faster rehabilitation for patients with significant injuries, including spinal injuries, or illness. Dr Putrino worked as a clinician in Australia, before moving to the United States to study computational neuroscience at Harvard Medical School, MIT and NYU. He has served as a faculty member at Weill-Cornell Medicine and Burke Medical Research Institute. He is currently the Director of the Abilities Research Center and is an Assistant Professor of Rehabilitation and Human Performance at the Icahn School of Medicine at Mt Sinai. The Advance Awards Overall Winner is chosen from ten diverse category winners and three special award winners, representing an extraordinary group of talented Australian leaders and innovators who have demonstrated excellence in their respective fields on the global stage, ranging from technology innovation, financial services and healthcare, to social impact, sustainability, and the arts. Advance Chairman Yasmin Allen said, “We are delighted David has been selected as our Advance Global Award winner. He is an inspiring global entrepreneur and innovator who is using unique technology to make people recover and rehabilitate faster from illness or injury, as well as to enhance athletic performance. At Advance, we know it is critical to recognise and celebrate the work of Australians like David and create an opportunity for them to remain connected with their ecosystem back home, for the benefit of all Australians. All our game-changing Award winners have again inspired, humbled and captivated us. Each year we build on this community to give Australians access to the very best thinking, opportunities and ideas, offshore and at home. We congratulate all our winners, and in particular David and look forward to continuing to connect Australia to our diaspora, making them household names back home.” More than 200 nominations were received from all around the world and winners of the Advance Awards were selected by a judging panel of renowned Australians who represent the country’s diverse entrepreneurial culture. Chaired by Advance Founder and Chairman Emeritus, Ken Allen AM, the judging panel includes Maggie Beer AM, Jillian Broadbent AO, Darren Burns, Doug Elix AO, Michelle Garnaut AO, Alexie Glass-Kantor, Sir Michael Hintze AM, Bob Isherwood, Andrew N. Liveris AO, and Carla Zampatti AC.                                                                                                         - ENDS - About Advance Advance is the only organisation to identify, engage and empower members of the global Australian diaspora. We keep them connected, and help repatriate ideas and IP home for the benefit of all Australians. With a community spanning 110 countries, Advance fosters connections with more than one million Australians living and working offshore, and 2.5 million student alumni, drawing on their experience and networks to open doors and opportunities for Australia, Australian companies and Australians around the globe. Website: LinkedIn: Twitter: @Advance Facebook: @AdvanceGlobal Instagram: @AdvanceGlobalAustralians Hashtag: #AdvanceAwards19 2019 Advance Award winners The 2019 Advance Awards category winners are: ●  Advanced Manufacturing Award — Adam Gilmour, CEO and Founder of Gilmour Space Technologies ●  Commercial Creatives Award — Natalie Jeremijenko AO, Artist/Engineer/Professor ●  Financial Services Award — Daria Rippingale, Founder and CEO of Bankingblocks ●  Food & Agriculture Award (joint winners) — David Thompson, Chef and Restaurateur and Michelle Grant, Faculty and Education Director at World Food System Center, Swiss Federal Institute of Technology (ETH Zurich) ●  Healthcare Award — David Putrino, Director of the Abilities Research Center and Assistant Professor of Rehabilitation and Human Performance at the Icahn School of Medicine at Mt Sinai ●  Social Impact Award — Richard Fuller OAM, Founder and President of Pure Earth 2 ●  Sustainability Award — Hugh Whalan, CEO of PEG Africa ●  Technology Innovation Award — Kate Glazebrook, CEO and Co-founder of Applied ●  The Arts Award — Angelica Mesiti, Artist The winners of three special awards are: ●  Global Alumni Award — Dr Laode Muhammad Syarif, Commissioner for Corruption Eradication Commission (KPK) ●  Asia Impact Award — Dr Yijia Li, Director of Public Translational Platform for Cell Therapy at Yangtze Delta Region Institute of Tsinghua University ●  Global Impact Award — Professor John Mattick AO, SHARP Professor at UNSW Sydney and Senior Research Fellow with Visiting University Professorship at Green Templeton College, Oxford About Dr David Putrino – 2019 Advance Award Overall Winner David is physical therapist with a PhD in Neuroscience. He worked as a clinician in Australia, before moving to the United States to study computational neuroscience at Harvard Medical School, MIT and NYU. He has served as a faculty member at Weill-Cornell Medicine and Burke Medical Research Institute. He is currently the Director of the Abilities Research Center and an Assistant Professor of Rehabilitation and Human Performance at the Icahn School of Medicine at Mt Sinai. He works to develop innovative technology solutions for individuals in need of better healthcare accessibility. He consults with the Red Bull High Performance division to use evidence-based technologies to improve athletic performance. He is also the “Chief Mad Scientist” of Not Impossible Labs, a group that crowd-sources accessible technological solutions for high-impact humanitarian problems. David’s research has been featured on the ABC, Sport’s Illustrated, the Wall Street Journal, the BBC, Time Magazine, TEDx, Wired and the New York Times to name just a few. He is the author of Hacking Health: How to make money and save lives in the HealthTech world, which is available from Amazon and Springer-Nature.  October 16, 2019 - World Spine Day “Get Spine Active” (#getspineactive) 2019-10-15T07:41:37Z october-16-2019-world-spine-day-get-spine-active-getspineactive   The New Zealand Chiropractors’ Association (NZCA) is urging Kiwis to get spine active and stay healthy as part of the NZCA’s contribution to World Spine Day (16th October 2019).   Back pain is the biggest single cause of disability on the planet, with one in four adults estimated to suffer from it during their lives.  With more than one billion people worldwide suffering from spinal ailments, all age groups are affected, from children to the elderly. On this year’s World Spine Day participating organisations are encouraging people to take steps to be kind to their spines.   New Zealand Chiropractors’ Association spokesperson and chiropractor Dr Cassandra Fairest says: `Movement is life.  Keeping your spine mobile while staying active helps to maintain flexibility and stability. With over 60 joints in your spine, it’s important that it functions well. Keeping mobile also helps to protect your spinal cord and nerves, as well as promoting good posture and nervous system health.’   ‘As we get older an accumulation of injuries and improper motion can cause wear and tear and associated aches and pains. But this doesn’t mean you need to stop moving – it means quite the opposite. Doing daily exercises to keep your spine functioning well may help to prevent your joints from becoming creaky and stiff. Just ask your family chiropractor what is right for you.’   Clinical guidelines in many countries now recommend spine and posture correction as front-line treatment ahead of any medication.[1]  The New Zealand website site has a range of simple exercises to help New Zealanders #getspineactive.   World Spine Day is focused upon raising global awareness of the importance of spinal health. With health professionals, exercise and rehabilitation experts, public health advocates, schoolchildren and patients all taking part.   Organised by the World Federation of Chiropractic on behalf of the Global Alliance for Musculoskeletal Health, World Spine Day has over 500 official supporters worldwide. More information about how to get involved is available at on Twitter (@world_spine_day), Instagram (@worldspineday), and Facebook (   New Zealand chiropractors are taking the lead to inform and inspire people to prevent pain and disability by educating the public to have a greater understanding of the relationship between their spine and nervous system, improving their posture, addressing and preventing spinal problems, and engaging in physical activity. Chiropractors are uniquely placed to provide care that specifically focuses on the health of the spine and the relationship between the spine and the nervous system.   ­Ends Further Information: Dr Cassandra Fairest, Chiropractor 021 242 3073 or Peter Boyes 027 554 0500 or   [1] Low back pain: a call for action Lancet Volume 391, No. 10137, p2384–2388, 9 June 2018 Hand-Washing More Effective Than Hand Sanitiser 2019-10-10T03:34:48Z hand-washing-more-effective-than-hand-sanitiser A new study has found washing your hands under running water removes the flu virus much faster than alcohol sanitizer – suggesting hand sanitizer might not be as effective as people think when fighting against the flu. The influenza A virus (IAV) remains infectious in wet mucus from infected patients, even after being exposed to an ethanol-based disinfectant (EBD) for two full minutes, report researchers at Kyoto Profectural University of Medicine, in Japan. Fully deactivating the virus, they found, required nearly four minutes of exposure to the EBD. The secret to the viral survival was the thick consistency of sputum, the researchers found. The substance’s thick hydrogel structure kept the ethanol from reaching and deactivating the IAV. “The physical properties of mucus protect the virus from inactivation,” said physician and molecular gastroenterologist Ryohei Hirose, PhD, MD., who led the study with Takaaki Nakaya, PhD, an infectious disease researcher at the same school. “Until the mucus has completely dried, infectious IAV can remain on the hands and fingers, even after appropriate antiseptic hand rubbing.” The study suggests that a splash of hand sanitizer, quickly applied, isn’t sufficient to stop IAV. Health care providers should be particularly cautious: If they don’t adequately inactivate the virus between patients, they could enable its spread, Hirose said. The researchers first studied the physical properties of mucus and found — as they predicted — that ethanol spreads more slowly through the viscous substance than it does through saline. Then, in a clinical component, they analyzed sputum that had been collected from IAV-infected patients and dabbed on human fingers. (The goal, said Hirose, was to simulate situations in which medical staff could transmit the virus.) After two minutes of exposure to EBD, the IAV virus remained active in the mucus on the fingertips. By four minutes, however, the virus had been deactivated. Previous studies have suggested that ethanol-based disinfectants, or EBDs, are effective against IAV. The new work challenges those conclusions. Hirose suspects he knows why: Most studies on EBDs test the disinfectants on mucus that has already dried. When he and his colleagues repeated their experiments using fully dried mucus, they found that hand rubbing inactivated the virus within 30 seconds. In addition, the fingertip test used by Hirose and his colleagues may not exactly replicate the effects of hand-rubbing, which through convection might be more effective at spreading the EBD. For flu prevention, both the Centers for Disease Control and Prevention and the World Health Organization recommend hand hygiene practices that include using EBDs for 15-30 seconds. That’s not enough rubbing to prevent IAV transmission, said Hirose. The study wasn’t all bad news: The researchers did identify a hand hygiene strategy that works, also sanctioned by the WHO and CDC. It’s simple: Wash hands, don’t just rub them. Washing hands with antiseptic soap, they found, deactivated the virus within 30 seconds, regardless of whether the mucus remained wet or had dried. Source: mSphere. Original Post The unlimited benefits of RTLS only with CarePlus™ Nurse Call 2019-10-09T01:44:46Z the-unlimited-benefits-of-rtls-only-with-careplus-nurse-call [Perth, Australia 9 October 2019] CarePlus™ is the market-leading care management destination for RTLS solutions and Nurse Call in the healthcare industry at NiQ Health, designing three targeted and integrated applications for different facilities, different people and different assets.   Each RTLS solution – CarePlus™ Mobile Staff Duress, CarePlus™ Asset Tracking and CarePlus™ Mobile Resident Call - can be fully integrated into CarePlus™ Nurse Call systems or installed as stand-alone devices with existing Nurse Call applications.   CarePlus™ Mobile Staff Duress and CarePlus™ Mobile Resident Call maximise safety, offering instant detect and direct responses when a portable tag is activated for assistance through 100% precise room locations. CarePlus™ Asset Tracking meanwhile ensures the management of important and costly equipment, certifying significant return on investment.  Advanced, clinical-grade Real-Time Location System (RTLS) and dual active technology RF (Radio Frequency) and IR (Infra-Red) is harnessed to automatically identify and track the location of assets and/or people in real time. Precise room accuracy location services guarantee indoor areas are effectively covered within any facility, of any size. CarePlus™ Mobile Staff Duress and CarePlus™ Mobile Resident Call also adhere to the recent Australian state governments recommendations to improve care standards in acute and aged care, valuing the need for greater staff and resident safety. CarePlus™ Mobile Resident Call has keenly observed the ongoing 2019 Royal Commission into aged care practices, noting any relevant recommendations.   For more information, please click here to visit our webpage.  Asthma Sufferers Unable to Reach Full Potential at Work 2019-10-07T05:40:35Z asthma-sufferers-unable-to-reach-full-potential-at-work The World Health Organisation estimates that 235 million people around the world suffer from asthma, however little is known about the impact of asthma on symptomatic people’s ability to work. This new research, published in the Journal of Asthma and Allergy, surveyed over 1,500 symptomatic asthma patients across six countries and found that, on average three out of four workers could not work to their full potential. Further, the survey indicated that asthma impacted the respondent’s emotional well-being, including mental strain and embarrassment. A research team, led by Dr Kevin Gruffydd-Jones from Box Surgery, Wiltshire, UK, invited a random selection of participants from Brazil, Canada, Germany, Japan, Spain and the UK to participate in an online ‘Work Productivity and Activity Impairment – Specific Health Problem’ survey developed by Research Now (London, UK). The survey quantified the impact of asthma on work time missed, loss of productivity while working and total work productivity loss for the seven days prior to the survey. In addition, the questionnaire asked the open-ended question, “How does your asthma at work make you feel?” to judge the impact of a patient’s asthma symptoms on their emotional well-being at work. Respondents were selected to participate in the survey if they were over 18 years old, diagnosed with asthma by a healthcare professional, currently employed full- or part-time and a long-term user of a controller inhaler or preventative medication. A total of 1,598 symptomatic patients completed the 5-minute survey between April and September 2015. The study results found that, on average, up to one-tenth (9.3%) of work hours were missed in a single week because of workers’ asthma symptoms. This averaged out to 5.4 work hours missed for both part- and full-time employees. Further, roughly three out of four (74%) workers reported being unable to work to their full potential because of their asthma, with 42% of workers experiencing a ‘prominent’ reduction in productivity. Workers commonly reported feeling challenged by respiratory symptoms, as well as tiredness/weakness, mental strain and physical impairments. Overall, total work productivity dropped by one third (36%) due to asthma.”But, what struck us most was the emotional response to asthma in the workplace,” explains Dr Gruffydd-Jones. “A significant number of patients felt guilt, shame and embarrassment when using inhalers at work.” Respondents also reported feeling inferior and disadvantaged compared to their non-symptomatic colleagues, and over two-thirds of respondents felt that asthma negatively impacted their work activities. Despite capturing a one-week snapshot from a working year only, without comparison with asymptomatic patients or personnel with no asthma, this study highlights the global issue of asthma in the workplace, its impact on productivity and the personal challenges it causes workers. The solution, Dr Gruffydd-Jones explains, requires a coordinated approach by clinicians, employers and occupational health teams. “Clinicians must ask patients about the impact of asthma on their work and employers must encourage their workers to seek medical help and provide an ‘asthma friendly’ environment. “This requires not only providing appropriate environmental controls but also a working environment that minimises embarrassment, such as allowing to staff to move out of the immediate work environment to use their inhalers.”   Source: Taylor and Francis Group MedAdvisor raises A$17.0 million in Placement with Investment Led by Leading US Healthcare Solution Provider HMS 2019-10-07T02:19:24Z medadvisor-raises-a-17-0-million-in-placement-with-investment-led-by-leading-us-healthcare-solution-provider-hms Melbourne, 7 October 2019 --- MedAdvisor Limited, Australia’s leading digital medication management company is pleased to announce that it has successfully raised A$17.0 million through a Placement (“Placement”) of 340,000,000 fully paid ordinary shares (New Shares) to cornerstone, sophisticated and professional investors at $0.05 per New Share. The New Shares are expected to be issued and commence trading on 14th October 2019. These New Shares will be issued under the company's existing placement capacity in accordance with Listing Rules 7.1 and 7.1A and will rank equally with all other ordinary shares on issue. The Placement received strong demand from institutional investors, with leading US healthcare analytics and technology business HMS, taking a pivotal cornerstone position of A$11.0 million alongside Australian institutional investors. This funding provides MedAdvisor with the capital required to execute identified opportunities in each market and to move to cash flow break even. Use of funds will include continued investment in MedAdvisor’s technology, sales and support to drive success in the US and the UK and support the Zuellig joint venture in South East Asia. In addition, funding will help drive domestic growth through sales and marketing to build on MedAdvisor’s market leading position with pharmacies and Australian consumers, and technology development to capitalise on the legislative shift to ePrescribing in Australia. Upon the completion of the transaction, HMS will be the largest shareholder in MedAdvisor with ~13% of the ordinary shares on issue, strengthening the register, joining existing strategic investors, EBOS Group and Sigma. About HMS HMS is a leader in healthcare payment accuracy and population health solutions with a significant US national footprint, including services to US federal government agencies, 40+ Medicaid agencies, 325 health plans, and more than 150 employer health programs. HMS is actively working in the Australian market as the lead US partner of the Digital Health Co-operative Research Centre (“Digital Health CRC”), the largest digital health research co-operative in the world, with funding from government, universities and businesses totalling over $200m (including funding from the Australian Government to cover a seven-year period from 2018). HMS is using its extensive patient engagement expertise to address several global healthcare behavioural challenges. MedAdvisor’s existing Australian business, capabilities and platform are well positioned to help support HMS’ goals of delivering innovative solutions that help healthcare organisations reduce cost, improve health outcomes and enhance patient satisfaction. Expanding MedAdvisor’s US Opportunity MedAdvisor’s Health Programs are designed to drive quality use of medicines, health literacy and medication adherence amongst patients through digital and in-person interactions and interventions. Through its partnership with Adheris in the US, MedAdvisor is marketing digital adherence programs (“DAPs”) to pharma companies who want to communicate with over 190m US patients through relationships with >26,000 pharmacies.  HMS brings a proven expertise in supporting health funders, including health insurers and governments, to improve patient health outcomes and reduce costs. Coupled with MedAdvisor’s proven expertise in the distribution of digital Health Programs, the partnership with HMS immediately extends the potential funders of MedAdvisor digital Health Programs to include US health plans and other health payors. New Board Member Mr Jeff Sherman, CFO and Treasurer of HMS, will join the board of MedAdvisor. Mr Sherman has more than 30 years of experience in the healthcare industry in key leadership positions. For the last 5 years Mr Sherman has been CFO and Treasurer of HMS Holdings Corp responsible for financial operations, corporate strategy and development. Previously Mr Sherman served as executive vice president and CFO of AccentCare, and executive vice president and CFO of LifePoint Hospitals Inc. Prior to that, he held senior finance and risk management positions at Tenet Healthcare Corporation. Robert Read, CEO of MedAdvisor commented: We are delighted that MedAdvisor’s strategy to leverage our patient health platforms in the US, Asia & most recently in the UK is endorsed by investors. This increased global reach is attracting high quality investors and to raise this funding at a premium provides strong endorsement.” Mr Read continued “HMS is an innovative healthcare solutions company that is expert in patient behaviour and analytics. HMS is also active in Australia, being the largest private partner of the Federal Government’s Digital Health CRC, which will provide opportunities to validate joint solutions. We are pleased to welcome Jeff Sherman to the board of MedAdvisor.”  Bill Lucia, Chairman and CEO of HMS commented: “HMS is building a diversified solutions business that is expert in identifying and addressing healthcare risks and cost; helping to build healthier population and sustainable healthcare systems. We continue to actively expand our solutions through internal product development and select, strategic acquisitions and investments. Our global search for innovative capabilities identified MedAdvisor for the services they can deliver to augment our offerings in both the US and Australia. We are looking forward to actively working with MedAdvisor to build significant value.” ---ENDS---   About MedAdvisor MedAdvisor is a world class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor’s highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over one million users through ~55% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with Adheris in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018, was recognised in the AFR Fast 100.  About HMS HMS was founded in 1974 and is based in Irving, Texas. HMS advances the healthcare system by helping healthcare organisations reduce costs and improve health outcomes. Through industry-leading technology, analytics and engagement solutions, HMS saves healthcare organisations billions of dollars annually while helping consumers live healthier lives. HMS provides a broad range of coordination of benefits, payment integrity and population health management solutions that move the healthcare system forward. A publicly traded company (NASDAQ: HMSY), HMS has more than 2,500 employees in 25+ offices across the US. For more information, visit   The new Breast Cancer App assisting women during breast cancer diagnosis, treatment and recovery 2019-09-30T03:45:58Z the-new-breast-cancer-app-assisting-women-during-breast-cancer-diagnosis-treatment-and-recovery Officially launching this October for Breast Cancer Awareness Month, an Australian company’s new app, Breast Cancer Recovery, will assist women globally who have been diagnosed with breast cancer, from their initial diagnosis through to their treatment and recovery. Breast Cancer Recovery’s founder, Sandra J De Poi, and the allied health medical team believe the app will make a positive difference to the lives of women going through the physically and emotionally challenging journey that is breast cancer. With over 15,000 women diagnosed with breast cancer each year in Australia, and over 2 million women globally, the Breast Cancer Recovery app empowers women during this uncertain and overwhelming time to make clear and informed choices in all areas of their life, and avoid the “Google overload” and confusion that often follows a breast cancer diagnosis. Breast Cancer Recovery provides a one-stop resource for women to achieve the best possible health outcomes, to optimise their treatment efficacy, to bounce back quicker, and to minimise their treatment side effects. The information in the app covers a range of topics including nutrition, food, recipes, fasting, vitamin D, lifestyle and mindfulness. Importantly, with recent research demonstrating the benefits of exercise during chemotherapy treatment, unique to Breast Cancer Recovery are its individualised exercise programs that can be undertaken in the comfort of the user’s own home and the app includes over 100 videos demonstrating each exercise. Lauren Locke, the physiotherapist on the Breast Cancer Recovery team was instrumental in designing the app’s exercise programs. “Often, going to the gym and exercising is one of the last things people undergoing breast cancer treatment feel like doing. Commonly, nausea, pain and fatigue are issues, so we wanted to create a tool that allowed women to undertake a researched exercise program in the comfort of their own home, at a time convenient to them,” Lauren says. Another member of the Breast Cancer Recovery team is Clinical Nutritionist, Megan Koerner, who used her biochemistry knowledge and experience to provide nutritional and lifestyle recommendations that have been proven to positively contribute to a breast cancer patient’s treatment and recovery. “All the content in the app is based on the latest clinical and scientific evidence-based research, and it was produced in consultation with oncologists and general practitioners. We made the app to give women support and to make their breast cancer journey less confusing, all the while complementing the advice and treatments of their medical practitioners. Even if women follow just two things in the app, it’s going to have a positive impact on their recovery,” Megan describes. Breast Cancer Recovery is available now for Apple and Android devices. App store links and further information can be found at